Aim is to move above 20% EBITDA, says GSK Pharma

2019-08-19 8 Dailymotion

From the Motilal Oswal 15th Investor Conference, Annaswamy Vaidheesh, vice president P-South Asia and India MD of Glaxosmithkline Pharmaceuticals shared his views and outlook.

Related Videos

Focussing on brands with higher margin & growth prospects, says GSK Pharma

PM Modi's demonetisation move was aimed at political gains, says BSP Chief Mayawati

Expect 30% growth on topline & 20% EBITDA growth in FY20, says IRB Infra

Expect 12-13% EBITDA Growth In FY19, Says Galaxy Surfactants

See incremental EBITDA of Rs 100-120 crore on merger of Tata Chemical consumer biz, says Rakesh Sony of Tata Global Beverages

Expect EBITDA margins to be in the late teens in next two-three years, says Radico Khaitan

GSK says tests hint Covid-19 drug fights Omicron

Move the Notting Hill Carnival from West London's narrow streets if Met says it's too dangerous, Chris Philip says

TikTok Responds To India Ban, Says Invited To Submit Clarifications; China Says Move Discriminatory

Not a single bullet fired despite border dispute with China says Modi and Trump says isolating Qatar is a good move